Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
for
Neoplasms
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 70+
Code: NCT04449549
Phase2, Recruiting
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors